SOURCE: Fresenius Renal Technologies

Fresenius Renal Technologies

July 15, 2015 09:25 ET

Now There's a Lightweight, Easier Way for Dialysis Patients to Have Treatments at Home

WALTHAM, MA--(Marketwired - Jul 15, 2015) - Fresenius Renal Technologies, a division of Fresenius Medical Care North America, announced today that it has combined the latest 2008K@home™ dialysis machine technology with the bibag® system, a lightweight, online dry bicarbonate solution made easy for patients. This bicarbonate powder is mixed with electrolytes prescribed by the physician and purified water that meets current hemodialysis standards.

The bibag bicarbonate system has numerous advantages from lightweight handling to reduced storage space in the home. It dissolves the bicarbonate powder directly at the machine to reduce the risk of contamination and bacterial growth. It also has an easy-top connection and integrated drain system to help prevent fluid spills when disconnected.

"We're committed to providing patients with effective home dialysis solutions," said Dr. Robert Kossmann, Senior Vice President and Chief Medical Officer of Fresenius Renal Technologies. "bibag is a great addition to the 2008K@home machine. It is convenient to use and less wasteful from an environmental standpoint."

With two bag sizes, patients are provided the right amount of bicarbonate for their prescribed treatment. The greatest difference the patient will notice is the small size and weight of the bibag compared to their current jugs of liquid bicarbonate. The bag design reduces waste costs and for patients who don't have a lot of storage space at home, bibag is a great solution because it dramatically decreases the storage area needed in the patient's home. 

About Fresenius Medical Care Renal Technologies
Fresenius Renal Technologies is North America's top producer of dialysis equipment, dialyzers and related disposable products. Fresenius Renal Technologies is a division of Fresenius Medical Care North America, the continent's leading provider of renal care, and designated as Forbes Magazine's World's Most Innovative Companies in 2011, 2012 and 2013. For more information about Fresenius Renal Technologies and Fresenius Medical Care North America, visit

This release contains forward-looking statements that are subject to various risks and uncertainties. Actual results could differ materially from those described in these forward-looking statements due to certain factors, including changes in business, economic and competitive conditions, regulatory reforms, foreign exchange rate fluctuations, uncertainties in litigation or investigative proceedings, and the availability of financing. These and other risks and uncertainties are detailed in Fresenius Medical Care AG & Co. KGaA's reports filed with the U.S. Securities and Exchange Commission. Fresenius Medical Care AG & Co. KGaA does not undertake any responsibility to update the forward-looking statements in this release. 

Contact Information